Dyadic Strengthens Collaboration with Israel Institute for Biological Research (IIBR) to Address Bio-Threats and Emerging Disease Solutions
Overview
Dyadic International, Inc. (NASDAQ: DYAI), a prominent biotechnology firm specializing in advanced microbial platforms for protein development and bioproduction, has announced a significant advancement in its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm, Life Science Research Israel (LSRI). The collaboration aims to target emerging diseases by leveraging Dyadic's expertise in microbial platforms for protein bioproduction and IIBR's capabilities in antibodies and antigens discovery.
Objectives of Partnership
• This partnership seeks to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats.
• By combining Dyadic's flexible scale protein bioproduction technologies with IIBR's antibodies and antigens discovery capabilities, the goal is to create effective treatments and vaccines to combat global health challenges.
• The intention is to eventually commercialize these solutions through collaborative out-licensing initiatives, although the current framework is non-binding and subject to the negotiation of a binding agreement.
Dyadic on Partnership
• Dyadic, expressed enthusiasm about advancing the collaboration with IIBR.
• The joint effort will involve enhancing Dyadic's C1 cell lines using proprietary gene sequences from IIBR to improve the biomanufacturing of recombinant vaccines and neutralizing agents, including targeted antigens and monoclonal antibodies.
• The focus is on addressing emerging diseases through global commercial out-licensing initiatives to enhance access and affordability of vaccines and antibodies.
Collab to Deal with Biothreats
• Baruch Shahar, General Manager of LSRI, highlighted the longstanding collaboration between LSRI and Dyadic, which began in January 2018 and expanded during the pandemic. Mr. Shahar emphasized their satisfaction with the ongoing work using Dyadic's C1 technology to co-develop vaccines and treatments for biological outbreaks, including pandemics and other threats.
• The collaboration aims to expedite the development of safe, protective, and cost-effective vaccines and treatments against various biothreat agents, including toxins, viruses, and bacteria.
